PET targeting the translocator protein (TSPO) represents an interesting approach for glioma visualization, as TSPO is highly expressed in tumor cells. We present a 32-year-old man with recurrent glioblastoma after multimodal treatment. PET with the novel TSPO ligand 18F-GE-180 was performed after reirradiation. Here, the previously reirradiated tumor showed a remaining circular TSPO expression. Moreover, cerebrospinal fluid dissemination was detected by a high focal uptake at the right lateral and at the fourth ventricle, whereas only a faint contrast enhancement was present in MRI. This case demonstrated the diagnostic potential of TSPO-PET for glioma imaging by visualizing even minimal disease burden.
From the Departments of *Nuclear Medicine, and
†Radiation Oncology, University Hospital, LMU Munich, Munich;
‡German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg
§Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg; and
∥Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
Received for publication January 23, 2018; revision accepted March 20, 2018.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Marcus Unterrainer, MD, MSc, Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr 15, 81377 Munich, Germany. E-mail: email@example.com.